Matches in SemOpenAlex for { <https://semopenalex.org/work/W2174811553> ?p ?o ?g. }
- W2174811553 endingPage "626" @default.
- W2174811553 startingPage "613" @default.
- W2174811553 abstract "Background and purpose Increased expression of P‐glycoprotein (PGP1) is one of the major causes of multidrug resistance (MDR) in cancer, including in osteosarcoma, which eventually leads to the failure of cancer chemotherapy. Thus, there is an urgent need to develop effective therapeutic strategies to override the expression and function of PGP1 to counter MDR in cancer patients. Experimental Approach In an effort to search for new chemical entities targeting PGP1‐associated MDR in osteosarcoma, we screened a 500+ compound library of known kinase inhibitors with established kinase selectivity profiles. We aimed to discover potential drug synergistic effects among kinase inhibitors and general chemotherapeutics by combining inhibitors with chemotherapy drugs such as doxorubicin and paclitaxel. The human osteosarcoma MDR cell lines U2OSR2 and KHOSR2 were used for the initial screen and secondary mechanistic studies. Key Results After screening 500+ kinase inhibitors, we identified NVP‐TAE684 as the most effective MDR reversing agent. NVP‐TAE684 significantly reversed chemoresistance when used in combination with doxorubicin, paclitaxel, docetaxel, vincristine, ET‐743 or mitoxantrone. NVP‐TAE684 itself is not a PGP1 substrate competitive inhibitor, but it can increase the intracellular accumulation of PGP1 substrates in PGP1‐overexpressing cell lines. NVP‐TAE684 was found to inhibit the function of PGP1 by stimulating PGP1 ATPase activity, a phenomenon reported for other PGP1 inhibitors. Conclusions and Implications The application of NVP‐TAE684 to restore sensitivity of osteosarcoma MDR cells to the cytotoxic effects of chemotherapeutics will be useful for further study of PGP1‐mediated MDR in human cancer and may ultimately benefit cancer patients." @default.
- W2174811553 created "2016-06-24" @default.
- W2174811553 creator A5017550859 @default.
- W2174811553 creator A5022352605 @default.
- W2174811553 creator A5033402435 @default.
- W2174811553 creator A5033769845 @default.
- W2174811553 creator A5034127151 @default.
- W2174811553 creator A5038077156 @default.
- W2174811553 creator A5066463949 @default.
- W2174811553 creator A5071532449 @default.
- W2174811553 creator A5082130171 @default.
- W2174811553 creator A5082326728 @default.
- W2174811553 creator A5083819670 @default.
- W2174811553 creator A5089893706 @default.
- W2174811553 date "2016-01-15" @default.
- W2174811553 modified "2023-10-05" @default.
- W2174811553 title "NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function" @default.
- W2174811553 cites W120347394 @default.
- W2174811553 cites W147439079 @default.
- W2174811553 cites W1501700213 @default.
- W2174811553 cites W154396870 @default.
- W2174811553 cites W1582696369 @default.
- W2174811553 cites W1964311086 @default.
- W2174811553 cites W1967945605 @default.
- W2174811553 cites W1969580999 @default.
- W2174811553 cites W1971375724 @default.
- W2174811553 cites W1971825415 @default.
- W2174811553 cites W1973522717 @default.
- W2174811553 cites W1981140460 @default.
- W2174811553 cites W1983329975 @default.
- W2174811553 cites W1986666514 @default.
- W2174811553 cites W1986690159 @default.
- W2174811553 cites W1987126752 @default.
- W2174811553 cites W1992018116 @default.
- W2174811553 cites W1994146214 @default.
- W2174811553 cites W1999906254 @default.
- W2174811553 cites W2003606323 @default.
- W2174811553 cites W2007988465 @default.
- W2174811553 cites W2014639631 @default.
- W2174811553 cites W2015050087 @default.
- W2174811553 cites W2016756053 @default.
- W2174811553 cites W2022408561 @default.
- W2174811553 cites W2037070803 @default.
- W2174811553 cites W2055904567 @default.
- W2174811553 cites W2056561005 @default.
- W2174811553 cites W2062581646 @default.
- W2174811553 cites W2062693894 @default.
- W2174811553 cites W2069907205 @default.
- W2174811553 cites W2074525949 @default.
- W2174811553 cites W2079967238 @default.
- W2174811553 cites W2088197122 @default.
- W2174811553 cites W2092815384 @default.
- W2174811553 cites W2106483532 @default.
- W2174811553 cites W2107281656 @default.
- W2174811553 cites W2115954319 @default.
- W2174811553 cites W2116716449 @default.
- W2174811553 cites W2117158587 @default.
- W2174811553 cites W2128271902 @default.
- W2174811553 cites W2145081899 @default.
- W2174811553 cites W2146260605 @default.
- W2174811553 cites W2152796692 @default.
- W2174811553 cites W2155966056 @default.
- W2174811553 cites W2160246128 @default.
- W2174811553 cites W2189963137 @default.
- W2174811553 cites W2191824243 @default.
- W2174811553 cites W2196064518 @default.
- W2174811553 cites W2282390010 @default.
- W2174811553 doi "https://doi.org/10.1111/bph.13395" @default.
- W2174811553 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4728419" @default.
- W2174811553 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26603906" @default.
- W2174811553 hasPublicationYear "2016" @default.
- W2174811553 type Work @default.
- W2174811553 sameAs 2174811553 @default.
- W2174811553 citedByCount "25" @default.
- W2174811553 countsByYear W21748115532016 @default.
- W2174811553 countsByYear W21748115532017 @default.
- W2174811553 countsByYear W21748115532018 @default.
- W2174811553 countsByYear W21748115532019 @default.
- W2174811553 countsByYear W21748115532020 @default.
- W2174811553 countsByYear W21748115532021 @default.
- W2174811553 countsByYear W21748115532022 @default.
- W2174811553 countsByYear W21748115532023 @default.
- W2174811553 crossrefType "journal-article" @default.
- W2174811553 hasAuthorship W2174811553A5017550859 @default.
- W2174811553 hasAuthorship W2174811553A5022352605 @default.
- W2174811553 hasAuthorship W2174811553A5033402435 @default.
- W2174811553 hasAuthorship W2174811553A5033769845 @default.
- W2174811553 hasAuthorship W2174811553A5034127151 @default.
- W2174811553 hasAuthorship W2174811553A5038077156 @default.
- W2174811553 hasAuthorship W2174811553A5066463949 @default.
- W2174811553 hasAuthorship W2174811553A5071532449 @default.
- W2174811553 hasAuthorship W2174811553A5082130171 @default.
- W2174811553 hasAuthorship W2174811553A5082326728 @default.
- W2174811553 hasAuthorship W2174811553A5083819670 @default.
- W2174811553 hasAuthorship W2174811553A5089893706 @default.
- W2174811553 hasBestOaLocation W21748115531 @default.
- W2174811553 hasConcept C114851261 @default.
- W2174811553 hasConcept C121608353 @default.